Exchange: NASDAQ·Updated 11:02 AM EDT

HCM News

News
all
press releases
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
Zacks
More News
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating...
Yahoo! Finance: News
HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low - What's Next?
HUTCHMED (NASDAQ:HCM) Hits New 12-Month Low - What's Next...
MarketBeat
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at...
MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why
HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why...
MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given an average rating of "Hold" by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold...
MarketBeat
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7%
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 278,317 shares, a decrease of 13.7% from the February 26th total of 322,619 shares. Currently, 0.2% of the...
MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy...
MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the stock, Marketbeat Ratings...
MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving Average - Here's Why
HUTCHMED (NASDAQ:HCM) Shares Pass Below Fifty Day Moving Average - Should You Sell...
MarketBeat

Advertisement|Remove ads.